Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory
The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
To evaluate the safety and efficacy of ReFacto in subjects with Hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
To compare FVIII:C levels determined using the one-stage and the chromogenic substrate assays at a central laboratory
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Inclusion Criteria: - Age ≥ 6 years - Male previously treated patients (≥150 Exposure Days) with moderate or severe hemophilia A (i.e. ≤ 5% FVIII:C) who will undergo elective major surgery that is anticipated to require at least 6 consecutive days of daily factor VIII (FVIII) infusions (surgical and post-surgical prophylaxis) - Ability to adhere to the protocol requirements Exclusion Criteria: - Hypersensitivity to ReFacto, murine allergen, or hamster allergen 2 History of FVIII inhibitor or current inhibitor, defined as > 0.6 BU - Prior participation in this study - Any concomitant bleeding disorder other than hemophilia A
6 Years - N/A
Accepts Healthy Volunteers
Medical Monitor, MD, ,
Wyeth is now a wholly owned subsidiary of Pfizer
Medical Monitor, MD, Study Director, Wyeth is now a wholly owned subsidiary of Pfizer